- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.11. | Harvard Apparatus Regenerative Technology, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11. | Harvard Apparatus Regenerative Technology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.10. | Harvard Apparatus Regenerative Technology, Inc.: Harvard Apparatus Regenerative Technology Announces Strategic Collaboration with Children's Hospital Capital institute of Pediatrics in Beijing, China ... | 58 | GlobeNewswire (Europe) | Holliston, MA, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) ("Harvard Apparatus Regenerative Technology" or the "Company"), a clinical-stage biotechnology... ► Artikel lesen | |
| 12.09. | Harvard Apparatus CEO buys $17,190 in company stock | 3 | Investing.com | ||
| 27.08. | Harvard Apparatus Regenerative Technology, Inc.: Harvard Apparatus Regenerative Technology Appoints Mao Zhang to Board of Directors | 2 | GlobeNewswire (USA) | ||
| 26.08. | Harvard Apparatus Regenerative Technology, Inc.: Harvard Apparatus Regenerative Technology Announces $5 Million Financing to Continue Clinical Trial | 2 | GlobeNewswire (USA) | ||
| 21.08. | Harvard Apparatus Regenerative Technology, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.08. | Harvard Apparatus Regenerative Technology, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| HARVARD APPARATUS REGENERATIVE TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 24.06. | Harvard Apparatus Regenerative Technology, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.05. | Harvard Apparatus Regenerative Technology, Inc.: Harvard Apparatus Regenerative Technology Reports First Quarter 2024 Financial Results and Recent Business Highlights | 97 | GlobeNewswire (Europe) | Entered into securities purchase agreements with accredited investors for a $1.5 million private investment in public equity (PIPE) financing. The transaction closed on April 15, 2024.Received $0.5... ► Artikel lesen | |
| 02.04. | Harvard Apparatus Regenerative Technology, Inc.: Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights | 168 | GlobeNewswire (Europe) | Established a Research Collaboration with the McGowan Institute for Regenerative Medicine at the University of Pittsburgh to Study the Repair and Regeneration of the Colon following ColectomyEstablished... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA | 0,162 | +1,00 % | Sernova Corp: Sernova enters product development LOI in Saudi Arabia | ||
| VITA 34 | 4,000 | -1,96 % | Original-Research: Vita 34 AG (von Montega AG): Vita 34 AG | Original-Research: Vita 34 AG - von Montega AG 27.11.2024 / 10:10 CET/CEST Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group AG. Für den Inhalt der Mitteilung... ► Artikel lesen | |
| GERATHERM MEDICAL | 4,020 | -2,43 % | Geratherm Medical Aktie: Rückschläge hinnehmen müssen | ||
| PLUS THERAPEUTICS | 1,210 | -4,42 % | Plus Therapeutics Announces Renewal Of Master Services Agreement With Telix | CANBERA (dpa-AFX) - Plus Therapeutics (PSTV) announced the renewal of its Master Services Agreement with Telix IsoTherapeutics Group. The MSA secures supply of cGMP Re-186, the radioisotope... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 1,156 | -1,70 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium | SEATTLE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical stage biopharmaceutical company developing innovative medicines in areas... ► Artikel lesen | |
| MEDICLIN | 2,540 | 0,00 % | EQS-News: MEDICLIN AG: Befreiung nach § 37 Abs. 1 und Abs. 2 WpÜG i.V.m. § 9 Satz 1 Nr. 1 WpÜG-AngebVO von den Pflichten nach § 35 Abs. 1 Satz 1, § 35 Abs. 2 Satz 1 WpÜG | EQS-News: MEDICLIN AG
/ Schlagwort(e): Sonstiges/Sonstiges
MEDICLIN AG: Befreiung nach § 37 Abs. 1 und Abs. 2 WpÜG i.V.m. § 9 Satz 1 Nr. 1 WpÜG-AngebVO von den Pflichten nach... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 | - Improved loss from operations by 31% -
- Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,520 | 0,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States | BOULDER, CO / ACCESSWIRE / November 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen | |
| NOVACCESS GLOBAL | - | - | NovAccess Global Inc. - 10-Q, Quarterly Report | ||
| TEMPUS AI | 56,29 | 0,00 % | Spotlight on Tempus AI: Analyzing the Surge in Options Activity | ||
| BRIGHTSPRING HEALTH SERVICES | 18,980 | 0,00 % | BrightSpring Health Services, Inc. Reports Third Quarter 2024 Financial Results and Increases Full Year 2024 Guidance | LOUISVILLE, Ky., Nov. 01, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
| ADAPTHEALTH | 9,580 | -4,58 % | AdaptHealth Corp. Announces Third Quarter 2024 Results | PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including... ► Artikel lesen | |
| MIMEDX | 9,550 | +1,81 % | MiMedx Group Stock Soars to 52-Week High of $9.62 | ||
| GENEDX | 75,03 | -2,86 % | GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights | STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the third... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 96,59 | 0,00 % | 5 Analysts Assess PROCEPT BioRobotics: What You Need To Know |
Das Unternehmen HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC kann der Branche Gesundheitswesen zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC finden Sie auf Wallstreet Online.
